Izrael - hebrejski - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

Izrael - hebrejski - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Izrael - hebrejski - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Izrael - hebrejski - Ministry of Health

rafa laboratories ltd - dipyridamole - טבליה - dipyridamole 75 mg - dipyridamole - dipyridamole - as an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. reduction of proteinuria in the nephrotis syndrome. treatment of membranoproliferative glomerulonephritis. prevention of pre-eclampsia in the final trimester of pregnancy. prevention of transplant artery stenosis. prevention of post-operative thromboembolic complications of coronary artery surgery. in combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. prevention of thrombogenic manifestations. as an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 10 mg - ramipril - ramipril - hypertension . congestive heart failure . reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 2.5 mg - ramipril - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical indust.ltd - ramipril 2.5 mg - tablets - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izrael - hebrejski - Ministry of Health

bayer israel ltd - sorafenib as tosylate - טבליות מצופות פילם - sorafenib as tosylate 200 mg - sorafenib - sorafenib - nexavar is indicated for the treatment of patients with advanced renal cell carcinoma. treatment of patients with hepatocellular carcinoma.